JHVEPhoto/iStock Editorial via Getty Images
- Merck (NYSE:MRK) is ceasing development of two monoclonal antibody candidates it was eying as fixed-doses combinations with its blockbuster Keytruda (pembrolizumab).
- Vibostolimab is an anti-TIGIT antibody, while favezelimab is an anti-LAG-3 antibody.
- The fixed-dose combination of vibostolimab and Keytruda was